by Mark Curtis | Mar 24, 2016
Welcome to your Update from the Clinic for the month of February. bluebird made its debut in the oncology market and treated its first patient with a chimeric antigen receptor (CAR) product targeting a novel antigen. Ziopharm enrolled its first patient in a study...
by Mark Curtis | Mar 15, 2016
Welcome to your deal review for the month of February. Astellas tied-off its acquisition of Ocata while GSK and Adaptimmune expanded their collaboration to develop cell-based immunotherapies. AVROBIO, a new cell and gene company based in Boston, Mass, and Toronto,...
by Stacey Johnson | Mar 4, 2016
Last week, I wrote about Dr. Leon Bellan’s creative solution to engineering artificial blood vessels for lab-grown organs: cotton candy! As much as I was impressed with his out-of-the-box thinking, I also really liked the excellent video produced by Vanderbilt...
by Nicole Kuchinsky | Feb 29, 2016
Japan is making bold moves to redefine how cell therapies make it to market, and the world is taking notice. In late January, the Japan External Trade Organization (JETRO) collaborated with the Centre for Commercialization of Regenerative Medicine (CCRM) to host a...
by Mark Curtis | Feb 22, 2016
Welcome to your update from the clinic for the month of January. It was a quiet month in the clinic. However, we did see some clearances for various clinical studies, including Fate’s ProTmune in GvHD and Pluristem’s PLX-R18 in hematopoietic recovery following bone...
by Mark Curtis | Feb 18, 2016
Welcome to your Cell Therapy Deal Review for the month of January. Things got off to a quick start with a number of cell-based immunotherapy companies announcing deals and research collaborations out of the gate, including a third acquisition by Juno. Juno...
Comments